1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Five Phase III Data Readouts To Look Out For In Q2

Crunch Time For Alexion, Aldeyra, Byondis, Novan

 
• By Kevin Grogan

Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.

Spotlight
Spotlight on Phase III data coming in the second quarter • Source: Alamy

Indication: Allergic conjunctivitis

Phase III data for Aldeyra Therapeutics Inc.’s reproxalap, an immune-modulating covalent inhibitor of reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, could see the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D